ResearchMoz added Latest Research Report titled ” Qutenza (Neuropathic Pain) – Forecast and Market Analysis to 2022 ” to it’s Large Report database.
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=198419
Qutenza (capsaicin 8% patch) was developed by NeurogesX, and is the first and only prescription-strength capsaicin treatment. It was approved in Europe (where is it marketed under license to Astellas Pharma) in March 2009 for the treatment of peripheral NP in non-diabetic adults, both as a monotherapy and in combination with other products. In the US, Qutenza was approved by the FDA in November 2009 for the treatment of PHN. NeurogesX retained the full commercial rights to Qutenza in the US and worldwide (outside Europe).
- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Qutenza including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Qutenza for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Clinical Manifestations of Neuropathic Pain – Signs and Symptoms 13
3.1.1 Painful Diabetic Neuropathy 15
3.1.2 Postherpetic Neuralgia 16
3.1.3 Trigeminal Neuralgia 16
3.2 Etiology and Pathophysiology 17
3.2.1 Etiology 18
3.2.2 Pathophysiology 19
4 Disease Management 27
4.1 Diagnosis and Treatment Overview 27
4.1.1 Diagnosis 27
4.1.2 Treatment Overview and Guidelines 34
5 Competitive Assessment 44
5.1 Overview 44
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/